Particle Therapy 2017

NRG (RTOG) – Phase III protocol – open for accrual

RADIATION THERAPY ONCOLOGY GROUP (RTOG 1308) PHASE III RANDOMIZED TRIAL COMPARING OVERALL SURVIVAL AFTER PHOTON VERSUS PROTON CHEMORADIOTHERAPY FOR INOPERABLE STAGE II-IIIB NSCLC

Stage • II • IIIA •IIIB

R A N D O M I

S T R A T I F Y

Both Arms : Consolida4on

Arm 1 : Photon dose—70 Gy*, at 2 Gy (RBE) once daily plus pla4num-based doublet chemotherapy

chemotherapy x 2 cycles required for pa4ents who receive concurrent carbopla4n and paclitaxel***

Histology • Squamous •Non-Squamous

Arm 2 : Proton dose—70 Gy (RBE), at 2 Gy once daily plus pla4num-based doublet chemotherapy**

Concurrent Chemotherapy Doublet Type • Carbopla4n/paclitaxel • Cispla4n/etoposide

Z E

*The total prescribed dose will be 70 Gy [Relative Biological Effectiveness (RBE)] without exceeding tolerance dose-volume limits of all critical normal structures .

Required Sample Size : 560 patients